This technology includes the use of a novel formulation for an engineered version of Fibroblast Growth Factor 1 (FGF1), TTHX1114, that can be used to accelerate regeneration of the corneal endothelium after surgical lesions. FGFs are well-established regulators of migration and proliferation of corneal endothelial cells (CECs).
The engineered FGF1, TTHX1114, is currently being commercialized.
Fibroblast growth factors 1 and 2 are currently used to accelerate healing in ocular surface wounds. These FGFs have three cystine residues that can lead to inactivation of the factor. The formulations in this technology remove these residues and result in the stable preservation of a functionally active recombinant FGF-1 (TTHX1114).